RPHM
NASDAQReneo Pharmaceuticals Inc.
Latest news
25 items- 13D/GAmendment: SEC Form SC 13D/A filed by Reneo Pharmaceuticals Inc.SC 13D/A - OnKure Therapeutics, Inc. (0001637715) (Subject)
- INSIDERPresident and CEO Saccomano Nicholas A was granted 4,556 shares (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Phillips Andrew John4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Mathers Edward T4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Manke Isaac4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERChief Financial Officer Leverone Jason A. was granted 16,331 shares (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Jansen Valerie Malyvanh4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Chief Scientific Officer Hartley Dylan4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Director Grey Michael G4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERDirector Carruthers R Michael was granted 4,939 shares (SEC Form 4)4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Agresta Samuel4 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Saccomano Nicholas A3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Phillips Andrew John3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Manke Isaac3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Leverone Jason A.3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Jansen Valerie Malyvanh3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hartley Dylan3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Carruthers R Michael3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- INSIDERSEC Form 3 filed by new insider Agresta Samuel3 - OnKure Therapeutics, Inc. (0001637715) (Issuer)
- SECReneo Pharmaceuticals Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - OnKure Therapeutics, Inc. (0001637715) (Filer)
- PROnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead program, OKI-219, in Q4-2024 -- Post-transaction cash, cash equivalents, and short-term investments of approximately $139 million expected to provide funding through multiple clinical readouts and runway into Q4-2026 -- Shares to trade on Nasdaq under the new ticker symbol "OKUR" commencing on October 7, 2024 BOULDER, Colo., Oct. 04, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ:OKUR) ("OnKure"), a clinical-stage biopharmaceutical company focused on the develo
- PRReneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure– Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") today announced the results of the special meeting of its stockholders held on September 26, 2024. At the special meeting, Reneo's stockholders voted in favor of all proposals, including the proposals required to complete the proposed merger of Reneo and OnKure, Inc. ("OnKure"). The closing of the merger is anticipated to take place on or around Friday, October 4, 2024. Following the closing of the merger, the combined company plans to change its name from "Reneo Pharmaceut
- SECSEC Form 425 filed by Reneo Pharmaceuticals Inc.425 - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
- SECSEC Form 8-K filed by Reneo Pharmaceuticals Inc.8-K - Reneo Pharmaceuticals, Inc. (0001637715) (Filer)
- 13D/GSEC Form SC 13G filed by Reneo Pharmaceuticals Inc.SC 13G - Reneo Pharmaceuticals, Inc. (0001637715) (Subject)
RPHM FAQ
7 questionsWhat does Reneo Pharmaceuticals Inc. do?
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.Where does RPHM stock trade?
Reneo Pharmaceuticals Inc. (RPHM) is listed on NASDAQ.What sector and industry is RPHM in?
Reneo Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Reneo Pharmaceuticals Inc. go public?
Reneo Pharmaceuticals Inc. (RPHM) completed its IPO in 2021.What are analysts saying about RPHM?
Reneo Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Market Perform on 2023-12-15. Recent price targets range from $145.00 to $400.00.What companies are similar to RPHM?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare RPHM side-by-side with any of them on Quantisnow.How can I track RPHM on Quantisnow?
Quantisnow aggregates Reneo Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RPHM to receive live email and push alerts on every new disclosure.